健脾止痒颗粒治疗特应性皮炎临床观察

目的探讨中药健脾止痒颗粒治疗特应性皮炎(AD)的有效性和安全性。方法将入选AD患者随机分为治疗组(健脾止痒颗粒)32例和对照组(氯雷他定)32例,连续服药4周。采用欧洲AD评分标准(SCORAD)对AD的临床严重度进行评分,用视觉模拟尺度(VAS)评分法对瘙痒程度进行评分;同时记录SCORAD积分和VAS积分。疗程结束后,评价疗效。结果治疗组及对照组治疗4周后,SCORAD积分下降(P<0.05)、VAS积分明显下降(P<0.01)。有效率前者为84.4%,后者为43.8%。两组疗效经统计学处理,差异有显著性(χ2=12,P<0.01)。两组病例未见明显不良反应。结论健脾止痒颗粒治疗AD疗效确切,能明显降低患者SCORAD积分和VAS积分。其有效机制有待深入研究。     

铍宝消炎癣湿药膏治疗疥疮的临床观察

目的：观察和评价铍宝消炎癣湿药膏治疗疥疮的临床疗效。方法：用铍宝消炎癣湿药膏均匀涂于疥疱患者自颈以下、遍布全身皮肤，每日2次，疗程3天。在治疗前与治疗后1周、2周随访时记录症状、体征积分，以评价疗效，并监测不良反应。结果：治疗后1周时痊愈率70％，总有效率83．3％；2周时，痊愈率93．3％，总有效率96．6％；1例出现局部不良反应。结论：铍宝消炎癣湿药膏治疗疥疮疗效好、安全性高。     

窄谱中波紫外线治疗特应性皮炎疗效观察及血清总IgE和EOS变化

目的观察窄谱中波紫外线(NBUVB)治疗特应性皮炎(AD)的疗效及治疗前后血清总IgE和末梢血嗜酸性粒细胞(EOS)计数的变化,以探讨治疗机制。方法给予64例AD患者NBUVB照射,每周3次,共12周;采用SCORAD计分系统对AD临床严重度进行评估;采用视觉模拟尺度评分法(VAS)对瘙痒程度进行评估;采用ELISA法检测血清总IgE。结果64例患者NBUVB治疗后12例痊愈,临床有效率86.2%;64例患者治疗前SCORAD和VAS积分以及血清总IgE和EOS计数较正常对照组水平升高,照射后显著下降。结论NBUVB是治疗AD的一种有效治疗方法;NBUVB可能是通过降低T细胞,抑制机体免疫来降低IgE和EOS。     

中药治愈融合性网状乳头瘤病1例

患者男,22岁,颈、胸、背红色或褐色斑丘疹、上附鳞屑,融合成片.诊断“融合性网状乳头瘤病”.笔者使用热毒清饮(自拟方)、灭癣净颗粒(院内制剂)及消炎癣湿药膏(铍宝)治疗,效果显著,临床治愈.     

润燥止痒胶囊在成人轻中度特应性皮炎治疗中的作用

目的探讨润燥止痒胶囊在成人轻中度特应性皮炎(Atopic Dermatitis,AD)治疗中的作用。方法将入选的AD患者随机分为治疗组32例,采用润燥止痒胶囊、凡士林乳膏和莫匹罗星软膏(百多邦)联合治疗;对照组21例,采用凡士林乳膏和莫匹罗星软膏治疗,均连续用药4周,采用SCORAD积分评价疗效。结果治疗组与对照组治疗前、后SCORAD积分均有所下降(P<0.01),治疗组的SCORAD积分下降明显大于对照组(P<0.05),治疗组的瘙痒积分明显下降(P<0.01),对照组的瘙痒积分无明显下降,治疗组有效率(62.50%)大于对照组(33.33%)。结论润燥止痒胶囊、凡士林乳膏和莫匹罗星软膏(百多邦)联合治疗成人轻中度AD可以改善病情,且润燥止痒胶囊可减轻瘙痒症状,并提高有效率。     

卡介菌多糖核酸注射液联合咪唑斯汀治疗特应性皮炎疗效评价

目的:评价卡介菌多糖核酸注射液联合咪唑斯汀治疗特应性皮炎(AD)的疗效。方法:治疗组AD患者70例,给予卡介菌多糖核酸注射液联合咪唑斯汀治疗;对照组50例给予咪唑斯汀治疗,治疗12周。通过治疗前后SCORAD积分和血清总IgE水平变化评价疗效。结果:治疗组有效率(61.4%)高于对照组(34.0%)。治疗组SCORAD积分和血清总IgE值下降水平明显大于对照组(P0.05)。结论:卡介菌多糖核酸联合咪唑斯汀治疗中轻度特应性皮炎疗效显著。     

保湿剂治疗婴儿湿疹疗效观察

干性皮肤是婴儿湿疹的主要症候，我科采用保湿剂联合铍宝消炎癣湿药膏治疗，婴儿湿疹取得较好疗效。     

铍宝药膏治疗疥疮60例疗效观察

目的：为了探讨在疥疮治疗方面安全有效，使用方便的药物和方法。方法：对60例疥疮应用铍宝消炎癣湿药膏外涂。早晚各1次，连用1w。治疗期间可每晚更衣、洗澡。结果：治疗后2w观察，治愈57例(95％)，显效2例(3．33％)，总有效率为98．33％。结论：铍宝消炎癣湿药膏治疗疥疮，具有疗效好，副作用小，安全性高的优点，是一种依从性好、可供临床选用的药物和疗法。     

金银花口服液治疗幼儿特应性皮炎的临床疗效观察

目的 观察金银花口服液治疗幼儿湿热型特应性皮炎（AD）的临床疗效及对患儿血清总免疫球蛋白E(IgE)和外周血嗜酸粒细胞的影响。方法 选择沈阳市第七人民医院2020年1月—12月收治的92例AD患儿按随机分为治疗组和对照组各46例。对照组口服盐酸西替利嗪滴剂,外用院内制剂湿毒洗剂和硼酸氧化锌软膏;治疗组在对照组的基础上加服金银花口服液,均连续治疗2周。比较2组AD严重程度评分指数（SCORAD）评分、血清总IgE、外周血嗜酸粒细胞水平及临床疗效变化,并记录不良反应发生情况。结果 治疗后治疗组SCORAD评分和总IgE、嗜酸粒细胞水平均明显低于对照组（P<0.05）;治疗组有效率为71.74%高于对照组的47.83%（χ2=5.47,P=0.02）,2组不良反应比较差异无统计学意义（χ2=0.19,P=0.66）。结论 金银花口服液治疗幼儿湿热型AD疗效明显,可以有效降低血清总IgE和外周血嗜酸粒细胞水平,且安全性高。     

外用铍宝消炎癣湿药膏治疗婴幼儿疥疮疗效观察

本科于2003年6月～2006年6月采用广东皮宝制药有限公司生产的铍宝消炎癣湿药膏治疗婴幼儿疥疮患者43例，取得了满意的疗效，现报道如下。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Multiple New-Onset Subcutaneous Nodules of the Upper Extremity Digits: Giant Cell Tumor of Tendon Sheath and Lipoma

A black woman with the concurrent onset of two subcutaneous nodules located on the digits of her upper extremities is described. Initially, a single systemic disorder was considered; yet, the lesions differed in morphology and consistency. Microscopic examination of the nodules showed a giant cell tumor of tendon sheath and a lipoma. Although Occam's “razor” suggests that multiple lesions in the same person are more likely to represent variable manifestations of a single disorder than several different diseases in that individual, the simultaneously appearing lesions in this patient represented two different conditions.